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Abstract
Background/objectives Preclinical investigations have
suggested that coating technology is crucial for the efficacy
of drug-eluting balloons (DEB). Aim of this study is to
compare the antirestenotic efficacy of two paclitaxel DEB
with different coatings in the treatment of in-stent
restenosis (ISR) by means of a morphological and func-
tional assessment.
Methods In a single center, prospective, non-randomized
study, the shellac-paclitaxel coated DIOR, and the urea-
paclitaxel coated IN.PACT Falcon were compared in the
setting of ISR. Quantitative angiography, fractional flow
reserve (FFR), and optical coherence tomography (OCT)
were performed at baseline, postprocedure and 6-month
follow-up. Main endpoints were QCA, FFR and OCT-
based parameters of restenosis.
Results Forty-five patients were included, 20 (44 %)
received treatment with the DIOR and 25 (56 %) with the
IN.PACT Falcon. Angiographic and device success were
100 and 90 % for the DIOR, and 100 and 92 % for the
IN.PACT Falcon, respectively. After 6-months, in-segment
late lumen loss (-0.03 ± 0.43 vs. 0.36 ± 0.48 mm,
p = 0.014) and diameter stenosis (30.7 ± 16.2 vs.
41.3 ± 22.6 %, p = 0.083) were lower for the IN.PACT
Falcon. FFR distal of the stent was significantly higher in
the IN.PACT Falcon group (0.92 ± 0.07 vs. 0.84 ± 0.13,
p = 0.029) and in-stent FFR gradient was lower
(0.05 ± 0.05 vs. 0.13 ± 0.12, p = 0.002). Between post-
procedure and follow-up, a 16 % decrease in neointimal
volume was observed for the IN.PACT Falcon, while a
30 % increase was observed for the DIOR (p = 0.006).
Conclusions The IN.PACT Falcon DEB showed higher
antirestenotic efficacy than the DIOR in the treatment of
ISR, demonstrating that DEB with an excipient-based
coating is not equally effective.
Keywords Drug-eluting balloon  In-stent restenosis 
Paclitaxel  Percutaneous coronary intervention
Introduction
Developments in stent design reduced the need for repeat
revascularization after percutaneous coronary intervention
(PCI). The lower revascularization rates following PCI are
predominantly due to the introduction of drug-eluting
stents (DES) which decreased the rate of in-stent restenosis
(ISR) compared to bare-metal stents (BMS). Across dif-
ferent indications and lesion types, the incidence of ISR at
one year has fallen below 5 % in new generation DES [1,
2]. Nevertheless, ISR still remains a significant problem
due to the large numbers of patients that undergo PCI with
stent implantation.
The challenging nature of ISR treatment is illustrated by
the numerous strategies that have been evaluated over the
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years. Implantation of a DES appeared most effective,
yielding better results than conventional balloon angio-
plasty alone [3, 4], cutting or scoring balloon treatment [5],
bare-metal stenting [6] and brachytherapy [7]. More
recently, the drug-eluting balloon (DEB) has been intro-
duced as an alternative approach to ISR [8]. Randomized
controlled trials (RCTs) have shown both clinical and
angiographic non-inferiority of paclitaxel DEB compared
to DES in BMS-ISR and DES-ISR [3, 9, 10]. Important
advantage of DEB angioplasty in ISR is the avoidance of
multiple layers of metal, providing more flexibility for
future repeat interventions on the target lesion.
However, not all DEB may be equally effective in ISR
[2]. The strength of DEB angioplasty resides in the sup-
pression of neointimal hyperplasia, the main cause of
recurrent ISR [11], by local delivery of an antiproliferative
drug (paclitaxel) [12]. The magnitude of neointima inhi-
bition depends on the ability of the DEB to create and
sustain sufficient tissue concentrations of drug at the target
lesion site. DEB coatings, designed to enhance the disso-
lution of paclitaxel from the balloon surface, are crucial to
this process [13]. Differences in coating technology, i.e.,
the type of solvent, excipient and coating method, may lead
to heterogeneity in the pharmacokinetic profile and thus
antirestenotic efficacy among DEB [13–15]. This was
previously observed in preclinical investigations and may
be reflected in the ambiguous results among clinical studies
investigating different DEB for identical indications [16,
17]. Data on head-to-head comparisons of DEB in the
treatment of patients with ISR are scarce, however [18].
Aim of this study is to compare the antirestenotic effi-
cacy of two established DEB with different coatings in the
treatment of ISR. Comparative assessment has been per-
formed by evaluation of DEB performance through serial
morphological and functional assessment using quantita-
tive coronary angiography (QCA), optical coherence
tomography (OCT), and fractional flow reserve (FFR).
Methods
Study design and patient selection
This study is a post hoc analysis of a prospective, single
center, and non-randomized study, which was originally
designed to elucidate the mechanism of action of DEB in
the setting of ISR. Patients with angina pectoris (both
stable and unstable) or silent ischemia, who were scheduled
for PCI because of ISR in a BMS or DES were regarded
eligible. Exclusion criteria were: acute myocardial infarc-
tion, left main disease, ostial ISR (unfit for OCT evalua-
tion), ISR located in a coronary bypass graft, recurrent ISR,
presence of renal failure (creatinine C200 lmol/L), left
ventricular ejection fraction B30 % and estimated life
expectancy\12-months. The study was approved by the
ethics committee of the University Medical Center Utrecht
and conducted in compliance with the Declaration of
Helsinki. All included patients provided signed informed
consent.
Interventional procedure
All study patients were treated with daily acetylsalicylic
acid (80–100 mg) and clopidogrel (75 mg). If not pre-
treated, a loading dose of clopidogrel (300–600 mg) was
administered before the procedure. Procedural anticoagu-
lation (aimed activated clotting time C250 s) was estab-
lished by intravenous heparin. Administration of
glycoprotein IIb/IIIa inhibitors was left at the physicians
discretion. After the procedure, acetylsalicylic acid was
continued indefinitely and clopidogrel was continued for
1 months.
Treatment of the target lesion was performed by
sequential standard balloon predilatation and DEB dilata-
tion. Standard balloons were sized with a 0.9:1 balloon-to-
index-stent-diameter ratio, with a length shorter than the
intended DEB, and inflated at high pressures (12–19 atm).
DEBs were sized with a 1.1:1 balloon-to-index-stent-di-
ameter ratio and inflated at lower pressures (6–10 atm) for
60 s. DEB length was selected to avoid geographic miss
(i.e., the DEB should extend C5 mm proximal and distal of
the predilatation balloon) and undesired DEB overlap in
case of multiple DEB use in long lesions. Device charac-
teristics are summarized in Table 1 and elaborated on in
the supplementary methods (Online Resource 1). Postdi-
latation with standard balloons was left at the physicians
discretion. Additional stenting was performed in case of
stent edge dissection or residual stenosis. Before com-
mencing PCI and directly afterwards, FFR and OCT were
performed consecutively. Predilatation with a small diam-
eter (1.5 or 2.0 mm) standard balloon was allowed in case
the target lesion could not be crossed with the FFR
guidewire or the OCT catheter at baseline. A detailed
methodological description of the acquisition and offline
analysis of QCA, OCT and FFR data is provided in the
supplementary methods (Online Resource 1).
Follow-up and endpoints
Angiographic follow-up was scheduled per protocol at
6 months, unless indicated earlier on clinical grounds.
Clinical follow-up was obtained simultaneously with
angiography or by telephone interviews at 6 months. All
clinical events were documented after careful examination
of relevant hospital files. Antirestenotic efficacy, the out-
come of interest, refers to the potency of the DEB to inhibit
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neointimal growth, not to the prevention of clinical
restenosis per se. Main endpoints of this study were
angiographic in-segment late luminal loss (LLL) and
diameter stenosis, percentage changes in FFR and OCT
parameters, and clinical outcomes according to the Aca-
demic Research Consortium criteria. Please see the Sup-
plementary Methods (Online Resource 1) for endpoint
definitions.
Statistical analysis
All data were analyzed using IBM SPSS Statistics software
version 20 (IBM Corp., Armonk, NY). Continuous vari-
ables were presented as mean ± standard deviation or
medians (interquartile range), as appropriate. Categorical
variables were reported as counts and percentages. Com-
parison of continuous variables was performed using the
Mann–Whitney U test, considering small group sizes.
Categorical variables were compared by means of Chi
Square or Fisher’s Exact Test. For the most important
outcomes, linear regression was used to adjust for differ-
ences in relevant baseline and procedural variables
between both groups. A two tailed p value B 0.05 was
regarded statistically significant.
Results
Forty-five patients were included in this study between
August 2009 and April 2013. Twenty-five patients (56 %)
were treated with the IN.PACT Falcon (results of this
cohort have been previously published) [19] and subse-
quently 20 (44 %) with the DIOR DEB. Baseline charac-
teristics of patients and lesions showed a high level of
resemblance between both treatment groups (Table 2). A
higher incidence of hyperlipidemia was observed in the
DIOR group (p = 0.01). The patterns of ISR were com-
parable between the groups. The majority comprised BMS-
ISR, while DES-ISR was present in 5 patients (25 %) in the
DIOR and three patients (12 %) in the IN.PACT Falcon
group (p = 0.44).
Angiographic and procedural success were 100 % in
both groups. One patient in the DIOR and 2 patients in the
IN.PACT Falcon group received additional stenting during
PCI, resulting in device success rates of, respectively, 95
and 92 %. Bailout stent implantation was required to
address coronary artery dissection at the proximal edge of
the old stent (n = 2, including the single DIOR patient)
and to treat residual significant stenosis just before the
proximal stent edge (n = 1). In the DIOR group, there was
a trend towards use of larger caliber predilatation balloons
(3.1 ± 0.4 vs. 2.9 ± 0.4 mm, p = 0.07) and shorter DEB
(27.3 ± 9.4 vs. 32.4 ± 12.0 mm, p = 0.10), the latter
reflecting shorter lesions. Details on procedural data are
provided in Table 3.
Angiographic outcomes and clinical follow-up
Angiographic data are presented in Table 4. Baseline
angiographic characteristics were similar between the
groups. In-segment LLL was significantly smaller for the
IN.PACT Falcon than for the DIOR (-0.03 ± 0.43 vs.
0.36 ± 0.48 mm, p = 0.014). The cumulative distribution
of in-segment LLL is depicted in Fig. 1 for both DEB. In-
segment diameter stenosis at follow-up was lower in
IN.PACT Falcon-compared to DIOR-treated patients
(30.7 ± 16.2 vs. 41.3 ± 22.6 %, p = 0.083), approaching
statistical significance. Binary restenosis (both in-stent and
in-segment) rate was 39 % in the DIOR and 17 % in the
IN.PACT Falcon group (p = 0.16).
Table 1 Device characteristics of the drug-eluting balloons
DIOR IN.Pact Falcon
Manufacturer EuroCor GmbH, Germany Medtronic Vascular Inc., USA
Balloon type Semi-compliant Semi-compliant
Balloon diameters available, mm 2.0, 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 2.0, 2.25, 2.5, 2.75, 3.0, 3.25, 3.5, 3.75, 4.0
Balloon lengths available, mm 15, 20, 25, 30 14, 20, 30, 40
Coated drug Paclitaxel Paclitaxel
Drug Paclitaxel Paclitaxel
Loading dose 3 lg/mm2 3 lg/mm2
Excipient Shellac Urea
Coating procedure Micro-pipetting Not specified
Inflation time, s 30–60 30–60
CE marking 2007 2009
CE Conformite´ Europe´ene
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Clinical follow-up at 6-months was available for all
patients (Table 4). There were no cases of cardiac death,
myocardial infarction or stent thrombosis during follow-up.
A strong trend towards a higher TLR rate was observed for
the DIOR as compared to the IN.PACT Falcon (35 vs. 8 %,
p = 0.057). Of the 7 DIOR and 2 IN.PACT Falcon patients
that received TLR, respectively 2 (29 %) and 1 (50 %)
presented with DES-ISR at baseline. All lesions treated
with TLR were FFR positive.
Fractional flow reserve and optical coherence
tomography
Fractional flow reserve measurements (Table 4) were per-
formed in 89 % (n = 40), 100 % (n = 45) and 91 %
(n = 41) of patients at baseline, postprocedure and follow-
up, respectively. Preprocedure FFR was forgone in five
patients as the FFR wire could not pass the target lesion,
postprocedure FFR was performed in all patients. FFR at
follow-up was missing in four patients who denied angio-
graphic follow-up. Baseline and postprocedure FFR distal
of the stent were comparable between the groups (p = 0.31
and p = 0.35, respectively), as were in-stent FFR gradients
(p = 0.54 and p = 0.40, respectively). At follow-up, FFR
distal of the stent was significantly higher in the IN.PACT
Falcon group (0.92 ± 0.07 vs. 0.84 ± 0.13, p = 0.029)
and in-stent FFR gradient was lower (0.05 ± 0.05 vs.
0.13 ± 0.12, p = 0.002).
Overall, preprocedural, postprocedural, and follow-up
OCT (Table 5; Fig. 2) were available in 78 % (n = 35),
96 % (n = 43), and 87 % (n = 39) of patients, respec-
tively, with no differences between the groups. Reasons for
missing OCT data were: the inability to cross the target
lesion (n = 8) and poor image quality (n = 2), at baseline,
technical issues with the acquisition catheter (n = 1) and
poor image quality (n = 1) just after the procedure, and the
refusal of follow-up angiography (n = 4) and poor image
quality (n = 2), at follow-up. Baseline OCT derived
lumen, neointima and stent characteristics were well mat-
ched between the groups. Postprocedure, mean and mini-
mal stent area were significantly smaller in the DIOR group
(both p = 0.02), while residual neointimal burden was
Table 2 Baseline patient and
lesion characteristics
DIOR (n = 20) IN.Pact Falcon (n = 25) p value
Patient characteristics
Age, years 66.6 ± 10.27 65.3 ± 9.69 0.66
Male gender 14 (70) 17 (68) 0.89
Diabetes mellitus 4 (20) 6 (24) 0.75
Hypertension 11 (55) 14 (56) 0.95
Hyperlipidemia 13 (65) 7 (28) 0.01
Current smoker 3 (15) 4 (16) 0.93
Family history of cardiovascular disease 10 (50) 12 (48) 0.89
Previous myocardial infarction 10 (50) 14 (56) 0.69
Previous coronary artery bypass grafting 3 (15) 3 (12) 0.77
Lesion characteristics
Target vessel 0.22
Left anterior descending 10 (50) 12 (48)
Ramus circumflex 6 (30) 3 (12)
Right coronary artery 4 (20) 10 (40)
Pattern of restenosisa 0.47
Focal body 8 (40) 5 (20)
Multifocal 0 0
Diffuse in-stent 8 (40) 15 (60)
Proliferative 3 (15) 3 (12)
Occlusive 1 (5) 2 (8)
Index stent type 0.44
Bare-metal stent 15 (75) 22 (88)
Drug-eluting stent 5 (25) 3 (12)
Index stent diameter, mm 2.97 ± 0.38 3.01 ± 0.47 0.64
Index stent length, mm 33.5 ± 14.5 28.6 ± 13.3 0.26
a Classified according to the Mehran classification
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comparable among the groups (similar mean and maximum
percentage neointimal area stenosis and percentage of stent
volume occupied by neointima). At follow-up, mean and
maximum neointimal area stenosis as well as neointima
occupied stent volume were larger for the DIOR group (all
p\ 0.05) with concomitant smaller minimal and mean
lumen area (both p\ 0.01). Stent strut analysis is depicted
in Supplementary Table 1 (Online Resource 1). In the
IN.PACT Falcon group, a small, but significantly larger
portion of overall uncovered stent struts was detected at
follow-up (p = 0.001), as practically all struts in the DIOR
group were covered.
Table 6 shows the percentage changes in postprocedure
and follow-up measurements. A percentage decrease in
minimal lumen diameter was observed for the DIOR, while
the IN.PACT Falcon showed a relative increase
(p = 0.034). Percentage volume changes revealed an
overall decrease in lumen and increase in neointima in the
DIOR group, as opposed to an increase in lumen and
decrease in neointima in the IN.PACT Falcon group
(Fig. 3). A significant difference was observed among the
DEB in the percentage change of in-stent FFR gradient
between postprocedure and follow-up, demonstrating an
in-stent gradient increase for the DIOR and a decrease for
the IN.PACT Falcon (p = 0.003). The difference in
neointimal growth and lumen volume change on OCT
remained statically significant after adjusting for hyperc-
holesterolemia, postdilatation, and postprocedure minimal
lumen area on OCT. Comparable differences were
observed when focusing only on BMS-ISR (see Supple-
mentary Table 2, Online Resource 1).
Discussion
The aim of this study was to compare the antirestenotic
efficacy (both morphological and functional) of two
established DEB with different coatings in the treatment of
ISR: the urea-paclitaxel coated IN.PACT Falcon and the
shellac-paclitaxel coated DIOR. Comparative assessment
of antirestenotic efficacy was performed by means of a
unique investigational approach, comprising serial mor-
phological (QCA and OCT) and functional (FFR) evalua-
tion of the target lesion.
The most important findings of this study are: (1) the
magnitude of neointimal inhibition is larger for the
IN.PACT Falcon than the DIOR DEB in the treatment of
ISR as demonstrated by the lower angiographic LLL and
decrease in neointimal volume on OCT at follow-up; (2)
the morphological changes detected in the IN.PACT Fal-
con group show favorable hemodynamics according to
FFR measurements; (3) the neointimal suppression
Table 3 Procedural features
DIOR (n = 20) IN.Pact Falcon (n = 25) p value
Predilatation with standard balloon 20 (100) 24 (96) 0.37
Predilatation balloon diameter, mm 3.1 ± 0.4 2.9 ± 0.4 0.07
Predilatation balloon length, mm 17.4 ± 5.4 20.7 ± 7.9 0.26
Predilatation pressure, ATM 14.8 ± 4.5 14.2 ± 5.0 0.71
[1 DEB used per lesion 2 (10) 6 (24) 0.27
DEB diameter, mm 3.2 ± 0.4 3.1 ± 0.3 0.34
2.50 2 (10) 1 (4)
2.75 0 3 (12)
3.00 9 (45) 13 (52)
3.50 8 (40) 8 (32)
4.00 1 (5) 0
DEB length, mm 27.3 ± 9.4 32.4 ± 12.0 0.10
DEB inflation pressure, ATM 10.8 ± 3.0 11.3 ± 3.0 0.54
DEB inflation time, s 58.0 ± 5.3 52.0 ± 13.2 0.18
Postdilatation with standard balloon 3 (15) 1 (4) 0.31
Maximum balloon diameter to index stent diameter ratio 1.09 ± 0.08 1.07 ± 0.09 0.34
Additional stenting 1 (5) 2 (8) 0.69
Angiographic success 20 (100) 25 (100)
Device success 18 (90) 23 (92) 0.69
Procedural success 20 (100) 25 (100)
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observed for the IN.PACT Falcon leads to less re-ISR
compared to the DIOR as shown by the trend towards
lower diameter stenosis and TLR rate.
Comparison with previous data
Antirestenotic efficacy was higher for the IN.PACT Falcon
compared to the DIOR, which resulted in a benefit in
clinical outcome. The present results for the IN.PACT
Falcon are in line with those previously reported for this
particular DEB. A small prospective study on BMS-ISR
observed an in-segment LLL of 0.02 ± 050 mm and TLR
rate of 4.3 % at 6 months [20]. In this regard, the IN.PACT
Falcon compares favorably to other benchmark DEB in the
setting of ISR [10, 21]. The findings for the DIOR are on
odds with prior data. In the Valentines-I trial, a prospective
study on the efficacy of the DIOR in both DES-ISR and
BMS-ISR, an encouraging 7.4 % TLR rate was found after
a mean follow-up of 7.5 months [22]. The lack of
mandatory angiographic and FFR follow-up may explain
the discrepancy with the present study findings.
Notably, the larger proportion of drug-eluting index
stents in the DIOR group had raised some concern for bias,
as recurrent restenosis is more common in DES-ISR
compared to BMS-ISR [2, 22]. Therefore, a subanalysis in
BMS-ISR patients was performed, which showed results
identical to the overall population (supplementary Table 2,
Online Resource 1). Other factors that have been associated
with recurrent restenosis, i.e., lesion length and ISR pattern
[23], were well balanced between the groups. Study design
Table 4 Quantitative
angiography and fractional flow
reserve measurements
DIOR (n = 20) IN.Pact Falcon (n = 25) p value
Preprocedural
Reference vessel diameter, mm 2.32 ± 0.51 2.35 ± 0.46 0.82
Minimal lumen diameter, mm 0.59 ± 0.28 0.58 ± 0.38 0.98
Diameter stenosis, % 75.0 ± 12.5 75.3 ± 16.1 0.94
Lesion length, mm 23.7 ± 9.5 26.4 ± 12.6 0.52
Fractional flow reserve 18 (90) 22 (88)
Distal of the stent 0.65 ± 0.11 0.58 ± 0.17 0.31
In-stent gradient 0.33 ± 0.12 0.37 ± 0.18 0.54
Postprocedural
Minimal lumen diameter, mm 1.88 ± 0.62 1.83 ± 0.47 0.79
Diameter stenosis, % 20.3 ± 9.17 27.5 ± 15.9 0.20
Acute gain, mm 1.29 ± 0.50 1.26 ± 0.61 0.85
Residual binary stenosis 0 2 (8) 0.50
Fractional flow reserve 20 (100) 25 (100)
Distal of the stent 0.93 ± 0.05 0.92 ± 0.05 0.35
In-stent gradient 0.05 ± 0.03 0.06 ± 0.04 0.40
Follow-up 18 (90) 23 (92)
Minimal lumen diameter in-stent, mm 1.46 ± 0.68 1.83 ± 0.62 0.064
Minimal lumen diameter in-segment, mm 1.41 ± 0.66 1.69 ± 0.56 0.11
Diameter stenosis in-stent, % 40.1 ± 23.9 26.0 ± 18.3 0.049
Diameter stenosis in-segment, % 41.3 ± 22.6 30.7 ± 16.2 0.083
Late lumen loss in-stent, mm 0.41 ± 0.54 0.01 ± 0.43 0.026
Late lumen loss in-segment, mm 0.36 ± 0.48 -0.03 ± 0.43 0.014
Binary restenosis in-stent 7 (39) 4 (17) 0.16
Binary restenosis in-segment 7 (39) 4 (17) 0.16
Fractional flow reserve 18 (90) 23 (92)
Distal of the stent 0.84 ± 0.13 0.92 ± 0.07 0.029
In-stent gradient 0.13 ± 0.12 0.05 ± 0.05 0.002
6-months clinical outcome 20 (100) 25 (100)
Cardiac death 0 0
Myocardial infarction 0 0
Stent thrombosis 0 0
Target lesion revascularization 7 (35) 2 (8) 0.057
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did not account for unmeasured confounding factors, such
as the pathophysiology and tissue characteristics of ISR.
Both features are closely related to the type of index stent,
however [24].
Importance of DEB coating technology
The present study confirms, for the first time using
mandatory angiographic follow-up, that no class effect can
be assumed for DEB in the clinical setting. An earlier
report from the SCAAR (Swedish Coronary and Angio-
plasty) registry has shown important differences in
restenosis between two commonly used DEB [2]. Of note,
the DEB compared in SCAAR were very dissimilar with
respect to the employed modifications to improve drug
release, as the DEB demonstrating the worse outcome
forgoes the use of an excipient. The pivotal role of
excipients in DEB was demonstrated before in preclinical
studies [13, 14] and is reflected in the ambiguous results of
clinical trials in small vessel disease [16, 17].
Despite both DEB in our study are equipped with an
excipient-based coating formulation, large differences in
antirestenotic efficacy are observed. This is best expressed
by the percentage changes in neointimal volume during
follow-up, revealing a 30 % increase for the DIOR and a
16 % decrease for the IN.PACT Falcon (Fig. 2). Where the
IN.PACT Falcon not only inhibits neointimal formation,
but also induces positive remodeling, the DIOR fails to
suppress neointimal growth to a sufficient degree. Positive
remodeling after DEB treatment may result from neointi-
mal smooth muscle cell loss due to paclitaxel-induced
apoptosis or necrosis, two phenomena that require high
local tissue concentrations of drug [25]. Otherwise, cica-
tricial shrinkage of neointima through healing of the
barotrauma-induced dissections may be involved [19].
Regardless of the underlying mechanism, the net effect of
these processes only becomes apparent as positive
remodeling in the presence of sufficient neointimal
suppression.
The observed disparity in antirestenotic efficacy may be
attributed to the difference in excipients, since all other
DEB characteristics were constant for both devices. Ani-
mal studies have suggested before that the use of an
excipient in a DEB coating is no guarantee for effective
drug transfer to the vessel wall [14]. However, early
paclitaxel tissue concentrations measured during the pre-
clinical testing of the DIOR were similar to those reported
for other established DEB [26, 27].
Fig. 1 Illustrative OCT imaging of the same coronary segment for
each time point (baseline, post-PCI and follow-up). Severe in-stent
restenosis at baseline (a and d). After PCI, lumen enlargement with
neointimal disruption and (micro) dissections are observed (b and e),
caused by the mechanical effect of DEB angioplasty. Follow-up
shows complete healing of the dissections with a moderate increase
(C) and limited decrease in neointima (F)
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According to more recent data, it may not be the acute
transfer of drug, but the durability of paclitaxel activity that
falls short in the DIOR. Using histological vascular healing
parameters (inflammation-, fibrin- and smooth muscle cell
loss score) as a proxy, the drug effect in DIOR treated
porcine arteries was observed to disappear rapidly as it was
already absent at one month follow-up [28]. This is
unsettlingly fast, as the vascular healing signs associated
with DEB well-known for their effectiveness remain even
detectable up to several months [29]. Thus, although
effective drug uptake does occur in DIOR angioplasty, its
effect appears short-lived. The cause of this unfavorable
pharmacokinetic profile of the DIOR remains speculative,
but may reside in an undesired drug-excipient interaction
that may lead to: (1) a decreased binding of paclitaxel to
non-specific binding sites accelerating its tissue clearance,
(2) a chemical configuration of paclitaxel that interferes
with its metabolic activity, or (3) less homogeneous release
of paclitaxel resulting in unfavorably large spatial
differences in tissue drug concentration. Interestingly, the
above data supports the longstanding presence of active
drug as the mechanism responsible for durable neointimal
inhibition by DEB, rather than the prevention of early
growth initiating events [27].
Investigational model
This study is the first in-human comparative assessment of
DEB using highly sensitive techniques to quantify mor-
phological and functional changes at the target lesion site.
The unique investigational approach ensued, allowed for a
precise and reliable assessment of antirestenotic efficacy.
While angiography is commonly used to assess neoin-
timal inhibition after DEB treatment, it remains lumenog-
raphy: an imaging technique providing data on lumen
diameter change at follow-up without differentiating
between the underlying mechanisms (neointimal growth or
stent recoil). In contrast, morphological assessment by
Table 5 Optical coherence
tomographic cross-section
analysis
DIOR (n = 20) IN.pact falcon (n = 25) p value
Preprocedure 16 (80) 19 (76)
Stent length analyzed, mm 23.9 [20.1–30.0] 22.0 [15.4–35.7] 0.29
Mean lumen area, mm2 3.1 [2.3–4.5] 3.6 [2.7–4.5] 0.32
Minimal lumen area, mm2 1.1 [0.7–1.4] 1.3 [0.9–1.8] 0.13
Mean stent area, mm2 6.5 [5.6–8.5] 7.2 [6.2–8.9] 0.31
Minimal stent area, mm2 5.3 [3.6–7.2] 5.4 [4.4–7.1] 0.32
Mean neointimal area stenosis, % 50.7 [35.4–66.1] 53.0 [43.7–58.9] 0.90
Maximum neointimal area stenosis, % 80.4 [74.2–88.7] 82.8 [73.6–85.9] 0.79
Lumen volume, mm3 89.7 [45.8–103.4] 77.4 [60.5–129.1] 0.92
Stent volume, mm3 156 [132–227] 176 [124–217] 0.92
Neointimal volume, mm3 66.4 [53.8–134] 87.4 [69.4–102] 0.53
Neointima occupied stent volume, % 51.5 [34.9–65.1] 53.2 [40.8–58.1] 0.95
Postprocedure 20 (100) 25 (100)
Stent length analyzed, mm 23.9 [19.7–29.9] 21.8 [15.6–32.0] 0.40
Mean lumen area, mm2 5.0 [4.1–6.8] 6.2 [5.5–7.1] 0.093
Minimal lumen area, mm2 3.3 [2.6–4.7] 4.7 [3.0–5.4] 0.10
Mean stent area, mm2 7.4 [6.0–9.7] 9.8 [8.8–11.0] 0.016
Minimal stent area, mm2 6.1 [4.1–8.5] 8.2 [7.5–9.2] 0.024
Mean neointimal area stenosis, % 28.3 [24.4–40.4] 33.5 [30.3–36.8] 0.58
Maximum neointimal area stenosis, % 47.8 [37.8–55.2] 48.3 [43.1–50.8] 0.96
Neointima occupied stent volume, % 28.2 [24.8–40.2] 33.6 [29.0–37.4] 0.38
Follow-up 17 (85) 22 (88)
Stent length analyzed, mm 23.8 [21.2–31.7] 22.4 [18.1–32.8] 0.28
Mean lumen area, mm2 4.6 [3.4–6.1] 6.0 [5.2–7.8] 0.008
Minimal lumen area, mm2 2.4 [1.8–3.7] 4.0 [3.1–6.0] 0.009
Mean stent area, mm2 7.6 [6.1–9.5] 9.1 [7.5–11.5] 0.066
Minimal stent area, mm2 6.5 [4.4–8.0] 7.7 [5.3–9.8] 0.16
Mean neointimal area stenosis, % 42.8 [23.7–55.3] 31.6 [24.9–37.5] 0.011
Maximum neointimal area stenosis, % 66.4 [49.9–76.6] 47.7 [37.3–60.7] 0.010
Neointima occupied stent volume, % 41.7 [26.0–55.1] 30.5 [23.7–36.5] 0.047
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OCT provides separate measurements on lumen, neointi-
mal and stent dimensions. This enables the precise calcu-
lation of neointimal dimension changes between specified
time points, irrespective of changes in stent volume.
Moreover, the OCT derived neointimal volume change at
follow-up represents neointimal inhibition along the entire
lesion length, whereas its angiographic counterpart (LLL)
may only reflect local neointimal suppression. Neointimal
volume change on OCT may thus provide a more honest
assessment of antirestenotic potency, although focal lumen
changes may be ultimately responsible for recurrent
restenosis.
Finally, structural functional assessment at follow-up by
means of FFR allowed for objective evaluation of the
impact of morphological changes on vessel patency. This
approach is highly recommendable, since a poor correla-
tion exists between angiographic assessment of moderate
or diffuse type ISR and the hemodynamic significance of
lesions assessed by FFR [30]. FFR confirmed the better
antirestenotic efficacy for the IN.PACT Falcon observed on
morphological data.
Limitations
Although baseline data were well matched between the
groups, the non-randomized design is an important limi-
tation of this study. Statistical correction for differences in
baseline characteristics was omitted because of the small
patient number in each treatment group. Notwithstanding
Fig. 2 Cumulative distribution of in-segment late lumen loss for the
DIOR and IN.PACT Falcon
Table 6 Percentage changes between postprocedure and follow-up
DIOR (n = 20) IN.pact falcon (n = 25) Crude p value Adjusted p value*
Quantitative coronary angiography 18 (90) 23 (92)
Minimal lumen diameter change, % –10.4 [–42.3 to 4.7] 4.8 [-7.7 to 16.8] 0.034 0.26
Diameter stenosis change, % 28.6 [-7.1 to 187] 2.6 [-49.7 to 67.6] 0.032 0.32
Optical coherence tomography 17 (85) 21 (84)
Minimal lumen area change, % -30.2 [-49.5 to 2.6] -13.4 [-21.8 to 19.4] 0.048 0.097
Maximal neointimal area change, % 33.8 [6.2 to 72.0] -8.9 [-21.0 to 33.0] 0.002 0.007
Maximal neointimal area stenosis change, % 35.8 [8.7 to 59.1] 14.6 [-21.7 to 36.6] 0.014 0.009
Lumen volume change, % -14.6 [-34.0 to 1.7] 2.89 [-14.0 to 18.6] 0.011 0.026
Stent volume change, % -0.7 [-3.0 to 2.7] -1.6 [-6.9 to 5.9] 0.67 0.77
Neointimal volume change, % 27.2 [1.1 to 58.6] -15.8 [-36.7 to 28.3] 0.006 0.028
Fractional flow reserve 17 (85) 22 (88)
FFR stent gradient change, % 69.0 [0.0 to 238] -40.8 [-58.9 to 18.8] 0.003 0.46
* Adjusted for differences in hypercholesterolemia, postdilatation and postprocedure OCT minimal lumen area
Fig. 3 Percentage changes in postprocedure and follow-up in stent,
neointima and lumen volumes derived from optical coherence
tomography (negative values represent a decrease and positive values
an increase in volumes during follow-up)
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the unequivocal results of the exhaustive analysis of anti-
restenotic efficacy in this study, our findings should be
interpreted in light of the small sample size. Although no
blinding was provided for QCA and OCT analysis, there
was only limited opportunity for observer bias as the
analyses were performed semi-automatically.
Conclusions
In this study comparing two commonly used DEB in the
treatment of ISR, the IN.PACT Falcon demonstrated higher
antirestenotic efficacy than the DIOR on both morpholog-
ical and functional parameters. This differential efficacy is
probably caused by the different excipients in the DEB
coatings, leading to different pharmacokinetic profiles.
Notably, both of the investigated devices have previously
shown antirestenotic benefit in preclinical and clinical
studies. Therefore, direct comparative assessment of DEB
in the clinical setting seems warranted, as currently avail-
able DEB may represent a spectrum of devices with an
antirestenotic efficacy anywhere between a standard
uncoated balloon and a ‘true’ DEB.
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